Clin2
NCT06353191Likely a fitRecruiting

Blood markers to predict heart problems from cancer therapy

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

Part of Blood & lymphatic, Cancer, Heart & circulation clinical trials.

This study looks for early warning signs (biomarkers) of heart damage caused by cancer treatments. It is for people who have had cancer treatment, may have heart issues, or are about to start a treatment that could affect the heart.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
693 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older
  • You have been treated for cancer with chemotherapy (pills or IV), immunotherapy, or other cancer therapy
  • You have had a heart problem possibly related to your cancer treatment, OR you completed treatment without heart problems at least 2 years ago, OR you are about to start a treatment that may affect the heart
  • You understand the study and can sign a consent form

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07621289Not yet recruiting
Predicting heart risks in cancer treatment

This study looks at whether doctors can predict heart problems caused by certain cancer treatments. It gathers information from patients before they start treatment to build better risk-checking tools.

NCT07663357Recruiting
Blood test to detect heart damage from breast cancer treatment

This study looks at whether a simple blood test can spot early signs of heart damage from certain breast cancer treatments (anthracycline chemo or anti-HER2 drugs). The goal is to protect your heart while you get the cancer treatment you need.

Fortaleza, Ceará
NCT05507879Recruiting
Breast cancer heart monitoring to predict heart damage risk

This trial studies how a blood test marker (TRPC6) may help predict and prevent heart muscle damage and heart failure related to some breast cancer medicines. You may join if you’re starting or have received treatment that can stress the heart, or if you already have signs of treatment-related heart problems.

Gainesville, Florida
NCT06900296Not yet recruiting
Blood markers to predict immunotherapy response and side effects

This study looks at blood samples from people with cancer who are starting immunotherapy. Researchers want to find markers that might predict how well the treatment works and whether it could cause side effects.

Indianapolis, Indiana
NCT07864467Not yet recruiting
Heart health monitoring during chemotherapy

This study follows patients receiving a type of chemotherapy called anthracyclines to track how it affects the heart over time. The goal is to learn how to better protect heart health during cancer treatment.

Darlington
NCT07060950Not yet recruiting
Blood markers study for people with cancer

This study looks for markers of cancer in your blood. It may help doctors learn more about your tumor and how to treat it.

Montpellier, France

Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.